The use of calcium hydroxyapatite ceramic in bone tumour surgery.
We report 60 benign bone tumours treated by resection and curettage followed by the implantation of calcium hydroxyapatite ceramic (CHA). After follow-up of six to 60 months (average 36), no patient had local recurrence of the tumour or any adverse effects from the implants. In almost all cases radiography showed that the CHA was well-incorporated into the host bone, with new bone formation in and around the CHA. Corrective remodelling of deformed bone and normal fracture healing suggested that there was normal bone turnover in the presence of the CHA. Histology of biopsies from seven patients showed bone ingrowth into the pore structure of CHA in the central zone of some defects by one year after implantation. CHA appears to be a useful substitute for bone graft in the treatment of some benign tumours.
Uchida
A
A
Department of Orthopaedic Surgery, Osaka University Medical School, Japan.
Araki
N
N
Shinto
Y
Y
Yoshikawa
H
H
Kurisaki
E
E
Ono
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000473:pathology; D002516:Ceramics; D002648:Child; D017886:Durapatite; D006801:Humans; D006882:Hydroxyapatites; D008722:Methods; D008875:Middle Aged; D011183:Postoperative Complications; D019736:Prostheses and Implants; D011859:Radiography
D006882:Hydroxyapatites; D017886:Durapatite